Department of Obstetrics and Gynecology, Cengiz Gokcek Women's and Children's Hospital, Gaziantep, Turkey.
Department of Gynecology and Obstetrics, Faculty of Medicine, Yuzuncu Yil University, Van, Turkey.
J Obstet Gynaecol. 2021 Aug;41(6):893-898. doi: 10.1080/01443615.2020.1819215. Epub 2020 Nov 24.
Preeclampsia (PE), the primary pathology of which is endothelial cell (EC) dysfunction, has long-lasting effects such as cardiovascular disease. Therefore, it was decided to investigate the maternal serum concentrations of EC-specific molecule-1 in patients with early-onset preeclampsia (E-PE). This study was conducted on 33 pregnant women with E-PE and 35 healthy pregnant women matched for gestational age. EC-specific molecule-1 level was measured using a commercially available enzyme-linked immunosorbent assay kit. The mean EC-specific molecule-1 concentrations were not significantly different between the groups (651.7 ± 632.2 pg/mL vs. 425.9 ± 263.0 pg/mL, =.056). Among women with E-PE, the median EC-specific molecule-1 concentration did not differ significantly by disease severity (=.115). EC-specific molecule-1 is not involved in the pathogenesis of E-PE. However, some studies in the literature report that EC-specific molecule-1 concentrations increased during the diagnosis of PE. Therefore, well-designed studies with a large sample are needed in cases of E-PE.Impact Statement There is an increased risk of cardiovascular disease (CVD) in early-onset preeclampsia (E-PE) which is linked with endothelial dysfunction. Endothelial cell (EC)-specific molecule-1 stands out as an important marker in EC dysfunction related conditions such as preeclampsia. This study showed that EC-specific molecule-1 is not associated with the CVDs risk linked with endothelial dysfunction in E-PE. Additionally, there was also no significant relationship was detected between the severity of E-PE and EC-specific molecule-1 concentrations. Endothelial cell-specific molecule-1 is not involved in the pathogenesis of E-PE. Moreover, advantageous and easy-to-measure markers are needed in larger sample studies to better understand the aetiology of E-PE.
子痫前期（PE）的主要病理表现为内皮细胞（EC）功能障碍，对心血管疾病等有长期影响。因此，决定检测早发型子痫前期（E-PE）患者的母血清中 EC 特异性分子-1 的浓度。本研究共纳入 33 例 E-PE 孕妇和 35 例年龄相匹配的健康孕妇。使用商用酶联免疫吸附试验试剂盒检测 EC 特异性分子-1 水平。两组间 EC 特异性分子-1 浓度的平均值无显著差异（651.7±632.2pg/mL vs. 425.9±263.0pg/mL，=0.056）。在 E-PE 患者中，疾病严重程度的 EC 特异性分子-1 中位数浓度无显著差异（=0.115）。EC 特异性分子-1 不参与 E-PE 的发病机制。然而，文献中的一些研究报告，在 PE 的诊断中，EC 特异性分子-1 浓度增加。因此，需要对 E-PE 进行设计良好、样本量大的研究。
E-PE 患者发生心血管疾病（CVD）的风险增加，与内皮功能障碍有关。内皮细胞（EC）特异性分子-1 在与内皮功能障碍相关的疾病中，如子痫前期，是一个重要的标志物。本研究表明，EC 特异性分子-1 与 E-PE 内皮功能障碍相关的 CVD 风险无关。此外，E-PE 的严重程度与 EC 特异性分子-1 浓度之间也未检测到显著关系。EC 特异性分子-1 不参与 E-PE 的发病机制。此外，需要在更大样本的研究中寻找更有利且易于测量的标志物，以更好地了解 E-PE 的病因。
